We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

42 hedge funds and large institutions have $700K invested in Oncolytics Biotech in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 41 → 42 (+1)

0.35% more ownership

Funds ownership: 1.23% → 1.59% (+0.35%)

36% less capital invested

Capital invested by funds: $1.09M → $700K (-$389K)

44% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 9

Holders
42
Holders Change
+1
Holders Change %
+2.44%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ARC
Advisor Resource Council
Texas
+$122K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$86.5K
3
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$43K
4
Morgan Stanley
Morgan Stanley
New York
+$39.6K
5
TSS
Two Sigma Securities
New York
+$24.9K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$18K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$16.1K
3
Renaissance Technologies
Renaissance Technologies
New York
-$14K
4
Fifth Third Bancorp
Fifth Third Bancorp
Ohio
-$12.2K
5
CIBC World Market
CIBC World Market
Ontario, Canada
-$9.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
ARC
1
Advisor Resource Council
Texas
$101K +$122K +100,000 New
Morgan Stanley
2
Morgan Stanley
New York
$93K +$39.6K +32,526 +55%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$70K +$86.5K +71,167 New
CIBC World Market
4
CIBC World Market
Ontario, Canada
$60K -$9.1K -7,486 -11%
Royal Bank of Canada
5
Royal Bank of Canada
Ontario, Canada
$44K -$1.65K -1,359 -3%
LFCM
6
Long Focus Capital Management
Puerto Rico
$40K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$34K – – –
Toronto Dominion Bank
8
Toronto Dominion Bank
Ontario, Canada
$34K +$43K +35,362 New
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$33K – – –
TSS
10
Two Sigma Securities
New York
$21K +$24.9K +20,512 New
BAM
11
Brave Asset Management
New Jersey
$20K – – –
LPL Financial
12
LPL Financial
California
$17K -$6.08K -5,000 -23%
Comerica Bank
13
Comerica Bank
Texas
$16K – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$14K -$14K -11,500 -45%
Stifel Financial
15
Stifel Financial
Missouri
$13K +$15.4K +12,662 New
Two Sigma Advisers
16
Two Sigma Advisers
New York
$11K -$16.1K -13,200 -55%
BCV
17
Banque Cantonale Vaudoise
Switzerland
$11K – – –
UBS Group
18
UBS Group
Switzerland
$11K +$12.2K +10,058 +6,096%
Osaic Holdings
19
Osaic Holdings
Arizona
$8K -$641 -527 -7%
CMA
20
Cedar Mountain Advisors
Oregon
$6K – – –
TRCT
21
Tower Research Capital (TRC)
New York
$6K +$6.41K +5,275 +557%
DI
22
Disciplined Investments
Oklahoma
$5K – – –
Rockefeller Capital Management
23
Rockefeller Capital Management
New York
$5K – – –
TCOV
24
Trust Company of Vermont
Vermont
$5K +$6.08K +5,000 New
Wells Fargo
25
Wells Fargo
California
$4K – – –
1
2

ONCY Hedge Fund Activity: Q2 2022 in Review

42 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q2 2022, worth a combined $700K — down 36% from $1.09M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ONCY positions and 6 closed out — a net gain of 1 holder — while 5 added to existing stakes and 9 trimmed.

The largest buyer was Advisor Resource Council, opening a new position worth an estimated $122K. The largest seller was Citadel Advisors, exiting entirely with an estimated $18K sold.

  • 42 institutional investors held Oncolytics Biotech (ONCY) as of Q2 2022, up from 41 in Q1 2022.
  • Funds reported $700K of Oncolytics Biotech stock for Q2 2022, down 36% quarter-over-quarter.
  • 7 funds opened new Oncolytics Biotech positions in Q2 2022 and 6 closed out, a net change of +1 holder.
  • The largest Oncolytics Biotech buyer in Q2 2022 was Advisor Resource Council, an estimated $122K added.
  • The largest Oncolytics Biotech seller in Q2 2022 was Citadel Advisors, an estimated $18K sold.

Based on aggregated 13F filings for Q2 2022.